Trial of Dexamethasone for Chronic Subdural Hematoma

Peter J. Hutchinson; Ellie Edlmann; Diederik Bulters; Ardalan Zolnourian; Patrick Holton; Nigel Suttner; Kevin Agyemang; Simon Thomson; Ian A. Anderson; Yahia Z. Al-Tamimi; Duncan Henderson; Peter C. Whitfield; Monica Gherle; Paul M. Brennan; Annabel Allison; Eric P. Thelin; Silvia Tarantino; Beatrice Pantaleo; Karen Caldwell; Carol Davis-Wilkie; Harry Mee; Elizabeth A. Warburton; Garry Barton; Aswin Chari; Hani J. Marcus; Andrew T. King; Antonio Belli; Phyo K. Myint; Ian Wilkinson; Thomas Santarius; Carole Turner; Simon Bond; Angelos G. Kolias

Journal ArticleOPEN ACCESS

Trial of Dexamethasone for Chronic Subdural Hematoma

Hutchinson P
Edlmann E
Bulters D
et al.

New England Journal of Medicine (2020) 383(27) 2616-2627

DOI: 10.1056/nejmoa2020473

251Citations

328Readers

Abstract

Abstract Background Chronic subdural hematoma is a common neurologic disorder that is especially prevalent among older people. The effect of dexamethasone on outcomes in patients with chronic subdu...

Cite

CITATION STYLE

APA

Hutchinson, P. J., Edlmann, E., Bulters, D., Zolnourian, A., Holton, P., Suttner, N., … Kolias, A. G. (2020). Trial of Dexamethasone for Chronic Subdural Hematoma. New England Journal of Medicine, 383(27), 2616–2627. https://doi.org/10.1056/nejmoa2020473

Trial of Dexamethasone for Chronic Subdural Hematoma

Abstract

Cite

Register to see more suggestions